Insider buying last 90 days
No open-market insider purchases were filed for HNGE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every HNGE insider filing, plotted on the chart in Gekko.Open HNGE in Gekko
NYSE: HNGE
Hinge Health (HNGE) Stock Analysis & Forecast
Sep 28 close
$92.45−3.12 (−3.3%)
Gekko Brief
AI summaryThis week's commentary on Hinge Health centers on its growth story and portfolio positioning rather than new corporate developments. Coverage includes a comparison with CorVel and a piece citing reasons to hold the stock, pointing to strong revenue growth, a raised 2026 outlook, and expansion into Migraine and GI care as supportive of its growth prospects. Separately, ETF ownership of HNGE shares was noted, and President James Pursley sold 33,000 shares on 21 September at an average price of $94.14, for a total transaction of $3,106,620.00.
HNGE closed at $92.45, down 3.3% on the day, though it remains above both its 50-day average of $87.31 and its 200-day average of $60.21, with the shorter average above the longer one. The GekkoIndex reads 56.7, placing the stock in the Neutral zone, up 4.8 over the last five sessions. Price sits 3.3% below Gekko Fair Value of $95.61.
The next earnings date falls on 3 November, 35 days out and beyond a typical 20-trading-day holding window; the prior report on 4 August showed EPS of $0.66 against a $0.28 estimate, with a 4% reaction. Smart-money activity over the past 30 days shows one unusual options signal, with put premium of $296,672 and no call premium recorded. Analyst consensus stands at 11 buy, 1 hold, 0 sell across 12 firms, with a consensus target of $108.07.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Hinge Health price vs fair value
Close $92.45200-day averageGekko Fair Value $95.61
Hinge Health quick facts
- Market cap
- $7.15B
- P/E ratio
- 11.6
- Forward P/E
- 33
- EPS, TTM
- $8.22
- Revenue, TTM
- $720.1M
- Profit margin
- 15.1%
- Dividend yield
- —
- Beta
- —
- Volume
- 1.19M avg 1.81M
- 1-year return
- +80.4%
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±13.1%
- 50-day average
- $87.31
- 200-day average
- $60.21
- Next earnings
- Nov 3 after close
- Shares outstanding
- 62.47M
Hinge Health swing-trade checklist
Hinge Health scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $92.45 is above the 50-day ($87.31) and 200-day ($60.21) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
56.7, Neutral
Reading 56.7 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.3% below
Price is within 5% of Gekko Fair Value (3.3% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Hinge Health stock chart and price history
Hinge Health closed at $92.45 on Sep 28, 2026, +80.4% over the past year, inside a 52-week range of $30.08 to $96.66.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −0.4%
- 3 months
- +13.5%
- 6 months
- +155.0%
- 1 year
- +80.4%
The full HNGE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HNGE in Gekko
Follow Hinge Health through every session
Put HNGE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track HNGE in GekkoFree for 7 days. No credit card required.
About Hinge Health
Hinge Health builds software aimed at musculoskeletal and joint health, giving people tools to address everyday joint and muscle issues, sudden injuries, ongoing chronic pain, and recovery after surgery. It is best known for offering a single platform that follows a patient through this whole range of musculoskeletal needs rather than treating each issue separately.
Beyond the clinical side of its platform, Hinge Health also handles administrative and operational support tasks tied to delivering this care, rounding out the service it provides.
Hinge Health was founded in 2012 and is headquartered in San Francisco, California. Its shares are listed on the NYSE under the ticker HNGE.
- Listed
- NYSE
- Sector
- Technology services
- Industry
- Packaged software
- Website
- hingehealth.com
Hinge Health GekkoIndex: the smart money zone
Hinge Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.7, in the Neutral zone, up 4.8 points over five sessions.
56.7Neutral
Up 4.8 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 19 | +3.7% | +22.5% | ||
| Accumulation | 74 | +2.8% | +6.9% | ||
| Neutral (current zone) | 195 | +0.5% | +4.2% | ||
| Distribution | 41 | +4.7% | +13.4% | ||
| Selling | 4 | Too few readings yet | |||
Average HNGE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the HNGE price, zone by zone.Track HNGE in Gekko
Is Hinge Health stock overvalued? Gekko Fair Value
Hinge Health trades 3.3% below Gekko Fair Value of $95.61, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Hinge Health shares are worth, recalculated every trading day.
$95.61
Gekko Fair Value, Sep 29, 2026
3.3% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open HNGE in Gekko
Hinge Health insider and Congress trading
No open-market insider purchases were filed for Hinge Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in HNGE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for HNGE, plotted on the chart in Gekko.Open HNGE in Gekko
Buybacks
Hinge Health has been buying back its own shares.
- Latest authorization
- $300.0M, Aug 4, 2026
- Bought back, quarter ended Jun 30, 2026
- $26.53M
- As a share of market cap
- 0.37%
From company filings.
Unusual options activity last 30 days
1signal, 0% of the flagged premium in calls.
Latest: Bearish flow on Sep 4, $297K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
3of the funds Gekko tracks hold HNGE.
2added1opened0trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Hinge Health earnings: next date and track record
Hinge Health reports on Nov 3, 2026, after the close (35 days away), and beat the EPS estimate in 6 of its last 6 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 35 days away
- EPS estimate
- $0.63
- Revenue estimate
- $223.7M
6 of 6reports beat the EPS estimate
±14.4%average move across the report
4 of 5reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Hinge Health reported a strong Q2 2026 with revenue of $213M (53% YoY growth) and LTM calculated billings of $862M (up 52% YoY). Management highlighted operating leverage (operating income doubled to $62M, operating margin expanded to 29%), gross margin improvement to 87% (benefitting from care-team efficiency and a one-time tariff refund), and materially higher free cash flow ($100M, 47% margin). The company emphasized product expansion—progress on migraine and entry into GI via the announced Cylinder acquisition—and strong commercial momentum across enterprise and SMB channels, including notable large-enterprise wins and improved win rates and pipeline. Management reiterated their platform strategy (unified app, cross-selling), noted yield improvements (guidance ~4.45%), and confirmed the Cylinder deal is expected to close late Aug/early Sep with ~$7M-$8M revenue contribution in 2026. They expect modest integration costs and affirmed long-term margin targets (35%+). The company also announced a $300M share buyback program. Q&A focused on Cylinder integration, yield drivers, competitive positioning, product rollouts, SMB dynamics, and Medicare opportunity.
- Guidance
- Includes Cylinder revenue of $7M-$8M for the remainder of 2026 (implying ~$20M-$25M annual run-rate for Cylinder); Q2 revenue was $213M (beat prior guidance of $200M-$202M). Yield guidance updated to ~4.45% (from ~4.3%). Long-term operating margin target reiterated at 35%+. Management expects Cylinder to expand meaningfully into 2028 after a full selling season. Additional commentary: Migraine expected to contribute ~10-20 bps of yield in 2027. Free cash flow and margin trajectory expected to remain strong; no detailed 2026 revenue or EPS numeric guide beyond inclusion of Cylinder and items discussed.
- Risks flagged
- Integration risk for Cylinder (product unification, potential integration costs over next ~9-12 months); Cylinder is a less mature company and ran at a modest loss historically; competitive pressure (other vendors claiming elevated win rates); reliance on sustained yield improvements (drivers include targeted enrollment, referrals, renewals); some benefit from a one-time tariff refund in Q2 (about 100 bps to gross margin); macro/procurement scrutiny that can lengthen sales cycles; regulatory, partner, and reimbursement risks referenced in standard SEC risk disclosures.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.66 est $0.28 | $212.8M est $201.5M | +4.0% |
| May 5, 2026 | $0.45 est $0.40 | $182.3M est $172.2M | +12.2% |
| Feb 10, 2026 | $0.49 est $0.43 | $170.7M est $156.7M | +20.5% |
| Nov 4, 2025 | $0.34 est $0.24 | $154.2M est $156.8M | −9.8% |
| Aug 5, 2025 | $0.67 est $0.09 | $139.1M est $132.4M | +25.6% |
| May 5, 2025 | $0.21 est $0.09 | $123.8M est $125.4M | — |
| Mar 10, 2025 | $0.35 | $117.3M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Hinge Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Hinge Health is $108.07, +16.9% from the last close, from 12 firms rating the stock in the last 90 days.
$108.07consensus 12-month target, +16.9% from the last close
Now $92.45Avg $108.07
Low $90High $125
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Truist Financial | — | — |
| Sep 22 | Robert W. Baird | $90 | −2.7% |
| Sep 8 | Stifel Nicolaus | $115 | +24.4% |
| Aug 24 | Morgan Stanley | $117 | +26.6% |
| Aug 11 | Truist Financial | $112 | +21.1% |
+4.2%average 20-day move after past Neutral readings
±4.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Hinge Health market cap and key statistics
Hinge Health’s market cap is $7.15B, with a P/E ratio of 11.6 and revenue of $720.1M over the last twelve months.
Valuation
- Market cap
- $7.15B
- P/E ratio
- 11.6
- Forward P/E
- 33
- EPS, TTM
- $8.22
- Gekko Fair Value
- $95.61
Trading
- Volume
- 1.19M
- Avg volume, 20 days
- 1.81M
- 52-week high
- $96.66
- 52-week low
- $30.08
- Shares outstanding
- 62.47M
Financials
- Revenue, TTM
- $720.1M
- Profit margin
- 15.1%
- Return on equity
- 30.4%
- Quarterly earnings growth, YoY
- −68.4%
Risk and income
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±13.1%
Hinge Health stock news this week
4 headlines about Hinge Health from the past week, newest first, each linking to the publisher.
- ETFs Investing in Hinge Health, Inc. Class A StocksTradingView, Sep 27
- Hinge Health (NYSE:HNGE) President James Pursley Sells 33,000 Shares of StockDefense World, Sep 24
- Critical Comparison: Hinge Health (NYSE:HNGE) & CorVel (NASDAQ:CRVL)Defense World, Sep 22
- Reasons to Hold Hinge Health Stock in Your Portfolio for NowZacks Investment Research, Sep 21
Hinge Health peers
Hinge Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MSFTMicrosoft | Neutral | 17.3% above |
| PLTRPalantir Technologies | Neutral | 15.7% above |
| ORCLOracle | Accumulation | 25.9% below |
| PANWPalo Alto Networks | Neutral | 16.1% above |
| CRWDCrowdStrike | Neutral | 27.2% above |
| CRMSalesforce | Neutral | 5.9% below |
A peer links to its own page where one exists.
Hinge Health stock FAQ
What is Hinge Health’s market cap?
Hinge Health’s market cap is $7.15B at the Sep 28, 2026 close of $92.45, with 62.47M shares outstanding. The shares trade on a P/E ratio of 11.6.
What is the Hinge Health stock forecast?
The consensus analyst 12-month price target for Hinge Health is $108.07, +16.9% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Hinge Health stock overvalued or undervalued?
On Gekko’s estimate Hinge Health is about fair value: the Sep 28, 2026 close of $92.45 is 3.3% below Gekko Fair Value of $95.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Hinge Health report earnings next?
Hinge Health is expected to report on Nov 3, 2026, after the market closes (35 days away). Analysts expect earnings of $0.63 per share on revenue of $223.7M. Hinge Health beat the earnings estimate in 6 of its last 6 reports, moving 14.4% on average across the report.
What is Hinge Health’s 52-week high and low?
Hinge Health’s 52-week high is $96.66 and its 52-week low is $30.08; it closed at $92.45 on Sep 28, 2026, +80.4% over the past year.
Is Hinge Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Hinge Health?
Gekko flagged 1 unusual options signal in Hinge Health over the last 30 days, with $0 of flagged premium in calls and $297K in puts. The latest, bearish flow, was on Sep 4, 2026 with $297K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Hinge Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.